UBS Group
LABT

UBS Group’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History

UBS Group’s Portfolio LABT Stock Details LABT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
+4,098
New +$70.3K ﹤0.01% 8425

Other funds holding LABT

MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

UBS Group's LABT Position: Q2 2026 in Review

UBS Group opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q2 2026: 4,098 shares worth $12.9K. The stake represents ﹤0.01% of the portfolio and ranks #8425 among its holdings.

6 funds tracked by Wall St. Rank hold LABT as of Q2 2026.

  • UBS Group held 4,098 shares of Lakewood-Amedex Biotherapeutics worth $12.9K as of Q2 2026.
  • Lakewood-Amedex Biotherapeutics was a new UBS Group position in Q2 2026.
  • Lakewood-Amedex Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8425 holding.
  • 6 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.